Yahoo Finance

NodThera Charts Obesity Future with First Patients Dosed in Phase 2 RESOLVE-1 Trial of Oral NLRP3 Inflammasome Inhibitor NT-0796

Philadelphia, PA, June 4, 2025 - NodThera, a leading clinical-stage biotech delivering a paradigm shift in the treatment of chronic inflammatory diseases through selective modulation of the NLRP3 ...
FiercePharma

Merck pits its pneumococcal shot against Pfizer's mammoth Prevnar in head-to-head phase 3

Merck & Co. has a big target in mind for its pneumococcal conjugate vaccine V114: no less than Prevnar 13, the world's best-selling shot. And now, the U.S. drugmaker has put V114 a phase 3 course that ...
Seeking Alpha

Bechtel and Woodside Place Woodside Louisiana LNG Phase 1 Order to Chart Industries

ATLANTA, Dec. 31, 2024 (GLOBE NEWSWIRE) -- Chart Industries, Inc. (GTLS) (“Chart”), a global leader in clean energy and industrial gas solutions, has received the order from Bechtel for the supply of ...
manilatimes

NodThera Charts Obesity Future with First Patients Dosed in Phase 2 RESOLVE-1 Trial of Oral NLRP3 Inflammasome Inhibitor NT-0796

NodThera Charts Obesity Future with First Patients Dosed in Phase 2 RESOLVE-1 Trial of Oral NLRP3 Inflammasome Inhibitor NT-0796 Pioneering small-molecule program, NT-0796, targets chronic ...